Table 1 Characteristics of the 125 breast cancer patients with paired pre- and post-chemotherapy specimens

Median age at diagnosis, years (IQR)

56 (49–63)

Ethnicity, n (%)

 Chinese

99 (79)

 Non-chinese

26 (21)

Histology, n (%)

 Ductal

110 (88)

 Lobular

8 (6)

 Other

7 (6)

TNM stage, n (%)

 I

20 (16)

 II

69 (55)

 III

35 (28)

 IV

1 (1)

ER status, n (%)

 Positive

83 (66)

 Negative

42 (34)

PR status, n (%)

 Positive

74 (59)

 Negative

51 (41)

HER2 status, n (%)

 Positive

55 (44)^a

 Negative

70 (56)

Genome-wide methylation, median (IQR)

0.655 (0.650–0.660)

Immune cell content (LUMP), median (IQR)

0.989 (0.988–0.990)

Cell type (proportion), median (IQR)

 CD19+ B-cell

0.004 (0.000–0.027)

 Natural killer cell

0.012 (0.000–0.036)

 CD4+ T cells

0.000 (0.000–0.035)

 CD8+ T cells

0.090 (0.064–0.122)

 Monocytes

0.061 (0.038–0.078)

 Granulocytes

0.796 (0.690–0.860)